BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update)
The article reports that BridgeBio Pharma's stock experienced volatility after announcing a settlement with Pfizer regarding patents for Vyndamax (tafamidis). The agreement allows BridgeBio to launch its tafamidis product, acoramidis, in October 2028, or earlier under specific conditions, and includes undisclosed financial terms. This resolution eliminates market uncertainty surrounding the patent dispute.
Jefferies Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100
Jefferies has reiterated its Buy rating for BridgeBio Pharma (BBIO.US) and maintained its price target of $100. This continued endorsement suggests the firm's confidence in the pharmaceutical company's future performance.
BridgeBio earnings up next: Attruby growth key amid competition
BridgeBio Pharma is set to release its first-quarter earnings, with focus on the commercial performance of its heart drug, Attruby, amidst increasing market competition. Analysts anticipate an improved financial quarter, expecting a loss of 68 cents per share on $178.2 million in revenue, driven by Attruby's launch despite a more competitive landscape and declining EPS estimates. Investors will be closely watching Attruby's market share growth, the company's path to profitability, and pipeline diversification efforts, particularly with upcoming Phase 3 results for encaleret.
Price to book forward of BridgeBio Pharma, Inc. – BX:BBIO
This article provides the "Price to book forward" financial metric for BridgeBio Pharma, Inc. (BBIO) on the BX Swiss exchange. It indicates that the market was closed at the time of publication, with no trades. The period, value, change, and change percentage for this metric are listed.
Enterprise value to revenue forward of BridgeBio Pharma, Inc. – FWB:2CL
The article provides a brief financial overview of BridgeBio Pharma, Inc. (FWB: 2CL) focusing on its enterprise value to revenue forward. It displays key financial data for the company on the Frankfurt Stock Exchange. The content includes a period value, change, and change percentage, indicating recent financial performance.
BridgeBio Pharma Raises $933.9 Million Via 7% Convertible Preferred From Sixth Street, HCRx
BridgeBio Pharma secured $933.9 million through an Investment Agreement for Series A cumulative convertible participating preferred stock from purchasers including Sixth Street and HCRx. This funding, featuring a 7.00% annual dividend and an initial conversion price of $137.79 per share, aims to strengthen liquidity and support development programs. The company also signed a Registration Rights Agreement to file a resale shelf for common shares, enhancing investor liquidity.
BridgeBio (Nasdaq: BBIO) secures $933.9M in senior convertible preferred equity
BridgeBio Pharma Inc. (Nasdaq: BBIO) has secured $933.9 million in senior convertible preferred equity financing from funds managed by Sixth Street and HealthCare Royalty. This capital infusion, which could reach $1 billion, significantly strengthens BridgeBio's balance sheet to support upcoming product launches, including for conditions like LGMD2I/R9, ADH1, and achondroplasia. The financing involves preferred stock with a 7% annual cumulative dividend and an initial conversion price of $137.79 per share, ranking senior to common stock on dividends and liquidation.
BridgeBio reports kidney function data for acoramidis in ATTR-CM
BridgeBio Pharma announced the publication of new data in Circulation: Heart Failure, revealing that acoramidis treatment for transthyretin amyloid cardiomyopathy (ATTR-CM) showed early, reversible improvements in kidney function and sustained reductions in urinary albumin to creatinine ratio. The analyses from Phase 2 and Phase 3 trials also indicated that patients experiencing an initial eGFR dip had a significantly reduced risk of death or cardiovascular hospitalization. This data underscores the cardiorenal benefits of acoramidis, which is approved in several regions under the names Attruby and BEYONTTRA.
BridgeBio Pharma Announces New Circulation: Heart Failure Analyses Showing Kidney-Protective Effects of Acoramidis in ATTR-CM
BridgeBio Pharma announced new analyses published in Circulation: Heart Failure, revealing that acoramidis demonstrates significant kidney-protective effects in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The data indicate rapid and sustained improvements in kidney function, including a reduction in urinary albumin to creatinine ratio (UACR) and an improved estimated glomerular filtration rate (eGFR) slope. These findings suggest acoramidis acts similarly to established kidney-targeting medications, offering unique cardiorenal benefits not observed with other ATTR-CM therapies.
BridgeBio secures $1 billion in convertible preferred equity
BridgeBio Pharma Inc. announced it has secured a $1 billion convertible preferred equity investment led by Sixth Street and HealthCare Royalty. The investment carries a 7.00% initial dividend and a conversion price premium of over 100%. BridgeBio, a biopharmaceutical company focused on genetic conditions, plans three potential U.S. product launches and has seen a 355% revenue surge over the last twelve months.
BridgeBio gets $1B from Sixth Street, HCRx for three launches
BridgeBio Pharma (Nasdaq: BBIO) has secured up to $1 billion in Series A cumulative convertible participating preferred equity from funds managed by Sixth Street and HealthCare Royalty. This financing, which includes an initial conversion price of $137.79 per share, aims to bolster BridgeBio's balance sheet and support the growth of its existing drug, Attruby, along with three potential U.S. product launches scheduled within the next 12 months. The agreement underscores investor confidence in BridgeBio's late-stage pipeline and strategic focus on genetic conditions.
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
BridgeBio Pharma, Inc. has secured $1 billion in convertible preferred equity investment led by Sixth Street and HealthCare Royalty, a business of KKR. This significant financing aims to strengthen BridgeBio's balance sheet, allowing for efficient capital allocation to high-return opportunities and supporting the growth of its blockbuster drug Attruby®. The funds will also help prepare for three additional potential U.S. product launches over the next year for BBP-418, encaleret, and infigratinib, addressing various genetic conditions.
Why BridgeBio Pharma (BBIO) Is Up 8.5% After NEJM-Published Infigratinib Phase 3 Achondroplasia Data
BridgeBio Pharma's stock rose 8.5% following the publication of positive Phase 3 PROPEL 3 data for its oral drug infigratinib in the New England Journal of Medicine. This data, which showed significant gains in height velocity and a favorable safety profile for children with achondroplasia, paves the way for regulatory filings in the US and EU starting in Q3 2026. The company's inclusion in Russell indexes and the potential for infigratinib to become a second growth pillar are highlighted, though the article also notes risks like high cash burn and dependence on other programs.
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Value Benchmark
BridgeBio Pharma, Inc. (NasdaqGS: BBIO) has been included in the Russell Midcap Value Benchmark. This update was reported on June 29, 2026, at 01:41 PM EDT. The company focuses on developing transformative medicines for genetic diseases, with a pipeline ranging from early science to advanced clinical trials for conditions like ATTR-CM, achondroplasia, and ADH1.
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Growth Benchmark
BridgeBio Pharma, Inc. (BBIO) has been included in the Russell Midcap Growth Benchmark. This news comes alongside recent analyst activities, including Mizuho cutting its price target and Canaccord Genuity initiating coverage with a "Buy" rating. BridgeBio Pharma is a biopharmaceutical company focused on developing treatments for genetic diseases, with several programs in various stages of clinical trials.
BridgeBio Pharma, Inc. (BBIO): Investor Outlook Highlights 45.61% Potential Upside Amid Robust Pipeline
BridgeBio Pharma (BBIO) is gaining investor attention with a robust pipeline of treatments for genetic diseases, including drugs for cardiomyopathy, molybdenum cofactor deficiency, and achondroplasia. Analysts project a 45.61% potential upside, driven by strong revenue growth of 66.80% and significant bullish sentiment despite current unprofitability and negative free cash flow. The company's technical indicators also suggest potential for further upward momentum.
BridgeBio Pharma Meets Primary Endpoint For Achondroplasia Drug in Phase 3 Trial
BridgeBio Pharma's investigational drug, infigratinib, achieved its primary endpoint in a Phase 3 clinical trial for achondroplasia, demonstrating a statistically significant increase in annualized height velocity. This positive outcome positions infigratinib as a potential treatment for the condition. The company plans to share additional details and discuss next steps with global regulatory authorities.
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell 1000 Growth Benchmark
BridgeBio Pharma, Inc. (NasdaqGS: BBIO), a biopharmaceutical company specializing in genetic diseases, has been included in the Russell 1000 Growth Benchmark. This news comes amidst recent analyst coverage, insider transactions, and FDA developments for their pipeline drugs. The company's stock shows a slight positive change for the day, despite recent price target cuts from some analysts.
BridgeBio Pharma Announces NEJM Publication and ICCBH Presentation of Positive Phase 3 PROPEL 3 Data for Oral Infigratinib in Achondroplasia
BridgeBio Pharma announced the publication of positive Phase 3 PROPEL 3 trial data for oral infigratinib in the New England Journal of Medicine and its presentation at the ICCBH conference. The study showed significant improvements in annualized height velocity and body proportionality for children with achondroplasia, positioning infigratinib as a potential best-in-class oral therapy. BridgeBio plans to submit an NDA to the FDA in Q3 2026 and an MAA to the EMA in H2 2026, with a target U.S. launch in early to mid-2027.
BridgeBio's achondroplasia drug posts NEJM Phase 3 data
BridgeBio (BBIO) announced the publication of positive Phase 3 PROPEL 3 trial results for oral infigratinib in children with achondroplasia in the New England Journal of Medicine. The study met its primary and key secondary endpoints, demonstrating significant improvements in height, body proportionality, and arm span. BridgeBio plans to submit an NDA to the FDA in Q3 2026 and an MAA to the EMA in H2 2026, with a potential U.S. launch in early to mid-2027.
BridgeBio (BBIO) Reports Positive Phase 3 Results for Infigratin
BridgeBio Pharma (BBIO) announced positive results from its PROPEL 3 clinical trial for oral infigratinib, targeting children with achondroplasia. The study showed significant improvement in height velocity and body proportionality, marking a key advancement in treating genetic disorders. Despite this clinical success, the company faces financial challenges, including negative earnings, a high price-to-sales ratio, a low GF Score for financial strength and profitability, and substantial insider selling, suggesting a speculative investment scenario.
BridgeBio Pharma, Inc. Actuals & Estimates (NASDAQ:BBIO)
This article provides an overview of BridgeBio Pharma, Inc. (NASDAQ:BBIO) stock performance, financial actuals, and analyst estimates. It covers the current stock price, historical highs and lows, future forecasts, market capitalization, and details from recent earnings reports, including revenue and net income.
BBIO Forecast — Price Target — Prediction for 2027
The article provides a forecast and price target for BridgeBio Pharma, Inc. (BBIO) stock, based on analyst opinions. It details the company's financial performance, including recent earnings and revenue, stock price history, and market capitalization. The consensus among analysts suggests a "strong buy" rating for BBIO stock, with a wide range for future price estimates.
BridgeBio Pharma (NASDAQ: BBIO) shareholders approve directors and add 2M plan shares
BridgeBio Pharma's (NASDAQ: BBIO) shareholders met on June 22, 2026, electing three Class I directors and approving several key proposals. These included advisory approval of executive compensation, annual frequency for future say-on-pay votes, and the ratification of Deloitte & Touche LLP as the independent auditor. Critically, shareholders also approved an amendment to the 2021 Stock Option and Incentive Plan, reserving an additional 2,000,000 shares of common stock for issuance.
Price to book forward of BridgeBio Pharma, Inc. – LS:A2PLX7
This article provides "Price to book forward" financial data for BridgeBio Pharma, Inc. (LS:A2PLX7) on TradingView. It shows the period, value, change, and percentage change for this metric, noting that the data is "Made by humans."
BridgeBio Pharma, Inc. Actuals & Estimates (MUN:2CL)
This article provides an overview of BridgeBio Pharma, Inc. (2CL) stock performance, financial actuals, and analyst estimates. Key information includes historical price data, upcoming earnings reports, and financial metrics like revenue, earnings per share, and EBITDA. The content also answers frequently asked questions about the company's stock on the Munich Stock Exchange.
BridgeBio Pharma (BBIO) director awarded RSUs and stock options
BridgeBio Pharma director Eric Aguiar was granted 3,990 restricted stock units (RSUs) and 5,277 stock options with an exercise price of $68.92 per share on June 22, 2026. Both the RSUs and options fully vest on June 22, 2027, contingent on his continued service on the board. After these awards, Aguiar directly holds 10,579 common shares and 5,277 stock options.
Enterprise value to revenue forward of BridgeBio Pharma, Inc. – LS:A2PLX7
This article displays the "Enterprise value to revenue forward" metric for BridgeBio Pharma, Inc. (LS:A2PLX7). Although specific financial data is not presented directly, the article highlights this particular financial ratio for the company. The page structure also indicates sections for overview, financials, news, community, technicals, forecasts, seasonals, bonds, and ETFs related to BridgeBio Pharma.
Form 4 BridgeBio Pharma Inc For: 24 June By Investing.com
This article from Investing.com is a regulatory filing update, specifically a Form 4 for BridgeBio Pharma Inc. dated June 24. It indicates an insider transaction or change in ownership for the company. The content itself is highly succinct, simply stating the filing and including a stock ticker with a minor price movement.
BridgeBio (BBIO) director sells 5,004 shares, receives RSU and option grants
BridgeBio Pharma director Hannah Valantine sold a total of 5,004 shares of common stock across two transactions at prices of $68.00 and $68.57 per share, as part of a pre-arranged Rule 10b5-1 sales plan. Concurrently, she exercised stock options for 2,808 shares at $41.73 each and received a grant of 3,990 restricted stock units (RSUs) vesting in 2027, along with a new stock option grant for 5,277 shares. Following these activities, her direct holdings stand at 9,259 shares, with an additional 398 held indirectly by her spouse.
Price to sales forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO
This page provides financial information for BridgeBio Pharma, Inc. (NASDAQ: BBIO), specifically focusing on its price-to-sales forward metric. The content highlights that the market was closed with no trades at the time of viewing. It also mentions that the data is sourced from ICE Data Services, FactSet, and Quartr for SEC filings.
Enterprise value to revenue forward of BridgeBio Pharma, Inc. – GETTEX:2CL
This article provides an overview of the "Enterprise value to revenue forward" metric for BridgeBio Pharma, Inc. (GETTEX:2CL) on TradingView. It shows that the market is currently closed with no trades. The piece highlights various financial metrics and information available for the company on the platform.
BridgeBio (NASDAQ: BBIO) director receives new RSU and stock option awards
BridgeBio Pharma director Andrew Lo was granted 3,990 restricted stock units (RSUs) and stock options for 5,277 shares of Common Stock. Both the RSUs and stock options will vest in full on June 22, 2027, contingent upon his continued service on the board. The stock options have an exercise price of $68.92 per share and expire on June 21, 2036.
BridgeBio Pharma (BBIO) director granted RSUs and stock options
BridgeBio Pharma director James C. Momtazee reported receiving 3,990 restricted stock units (RSUs) and a stock option for 5,277 shares, both vesting on June 22, 2027. The RSUs do not have an exercise price, while the stock option's exercise price is $68.92 per share. Additionally, 80,000 shares previously reported as directly owned by Momtazee have been reclassified as indirectly owned through the James C. Momtazee Revocable Trust.
BridgeBio Pharma (BBIO) director Fred Hassan granted RSUs and stock options
BridgeBio Pharma director Fred Hassan received 3,990 restricted stock units (RSUs) and stock options for 5,277 shares. Both the RSUs and options vest in full on June 22, 2027, contingent on his continued service on the board. After these grants, Hassan directly holds 29,879 common shares and options for 5,277 shares with an exercise price of $68.92, expiring on June 21, 2036.
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity
BridgeBio Pharma director Ali J. Satvat reported receiving equity awards consisting of 3,990 restricted stock units (RSUs) and a stock option for 5,277 shares. Both awards vest in full on June 22, 2027, contingent upon his continued service on the board. The stock option has an exercise price of $68.9200 per share and expires on June 21, 2036.
BridgeBio Pharma (BBIO) director awarded RSUs and options vesting 2027
BridgeBio Pharma director Ronald J. Daniels was granted 3,990 restricted stock units (RSUs) and a stock option for 5,277 shares of common stock. Both equity awards fully vest on June 22, 2027, contingent upon his continued service on the company's board. Following these awards, Daniels directly holds 20,981 shares of BridgeBio common stock, and the filing indicates no open-market buys or sells.
BridgeBio (NASDAQ: BBIO) awards RSUs and stock options to director
BridgeBio Pharma, Inc. (NASDAQ: BBIO) director Ellis Andrea received new equity awards, including 3,990 restricted stock units (RSUs) and a stock option for 5,277 shares. Both awards vest in full on June 22, 2027, contingent on continued board service. The stock option has an exercise price of $68.92 per share and expires on June 21, 2036.
BridgeBio Pharma (BBIO) director sells stock, exercises options and receives RSUs
BridgeBio Pharma director Jennifer E. Cook engaged in several transactions, including selling 37,167 shares at $70.00 and 2,196 shares at $68.57. She also exercised options for 17,167 shares at $16.75 and 20,000 shares at $8.45, and received 3,990 restricted stock units and an option for 5,277 shares at $68.92. Following these activities, Cook directly holds 8,383 shares, with at least one sale conducted under a Rule 10b5-1 trading plan.
Is BridgeBio (BBIO) One of the Best Upside Stocks to Buy According to Hedge Funds?
BridgeBio Pharma Inc. (NASDAQ: BBIO) is being highlighted as a top upside stock by hedge funds after the FDA accepted its NDA for BBP-418, an oral therapy for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The therapy, which has been granted Priority Review with a target action date of November 27, could become the first approved treatment for any form of LGMD and shown strong efficacy in Phase 3 trials. BridgeBio is also pursuing expedited approval in Europe and plans to expand clinical studies.
Is BridgeBio Pharma (BBIO) Undervalued As Rare Disease Launch Hopes Face A Rich P/S?
BridgeBio Pharma (BBIO) is currently trading at $68.63, with analysts estimating a fair value of $102.71, suggesting it is 33% undervalued due to its late-stage rare disease pipeline. Despite a strong 1-year total return of 54.4%, recent share price weakness points to cooling enthusiasm. However, the stock carries a high Price-to-Sales (P/S) ratio of 23.2x, significantly above the industry average, raising questions about whether future growth is already priced in.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. announced that its compensation committee approved equity grants to 30 new employees. These grants, totaling 66,810 shares of common stock in restricted stock units, serve as an inducement for their employment under Nasdaq Listing Rule 5635(c)(4). The grants will vest quarterly after an initial one-fourth vests on May 16, 2027, contingent on continued employment.
Bridgebio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Bridgebio Pharma has reported inducement grants that were made in accordance with Nasdaq Listing Rule 5635(C)(4). The article is a brief statement from Refinitiv, indicating the company's compliance with these specific listing regulations.
BridgeBio Pharma (BBIO) director has 788 shares withheld for RSU taxes
BridgeBio Pharma director Charles J. Homcy had 788 common shares withheld at $66.27 per share to cover tax obligations related to the vesting of 2,196 restricted stock units (RSUs). This transaction is a non-market disposition for tax purposes and not an open-market trade expressing a view on the stock. Following this, Homcy directly holds 915,886 shares of BridgeBio common stock.
Form 4 BridgeBio Pharma Inc For: 23 June By Investing.com
This article announces the filing of Form 4 for BridgeBio Pharma Inc. on June 23. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by corporate insiders. The article provides the title and date of this filing, along with the stock symbol BBIO.
BridgeBio lures 30 new employees with 66,810 share grants
BridgeBio Pharma announced grants of 66,810 restricted stock units (RSUs) to 30 new employees on June 18, 2026, as an inducement for their employment under Nasdaq Listing Rule 5635(c)(4). These RSUs will vest over time, with one-fourth vesting on May 16, 2027, and the remainder quarterly thereafter, contingent on continued employment. The grants are intended to attract talent and are part of an equity plan adopted in 2019 and amended in 2023.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. announced that its compensation committee approved equity grants to 30 new employees. These grants consist of restricted stock units totaling 66,810 shares of the Company's common stock. The awards were made as an inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4).
What BridgeBio Pharma (BBIO)'s New Phase 3 Infigratinib Data Reveal About Its Rare Disease Strategy
BridgeBio Pharma (BBIO) announced additional positive Phase 3 data for oral infigratinib in children with achondroplasia, alongside other clinical and quality-of-life studies for skeletal dysplasias and hypocalcemia. These findings, to be presented at a medical conference, reinforce BridgeBio's strategy to address both clinical outcomes and patient experience in rare diseases. The new data could positively influence the company's investment narrative and pipeline prospects, although high cash burn and financing risks remain.
BridgeBio Pharma, Inc. SEC Filing
This article reports on a Form 144 SEC filing by BridgeBio Pharma, Inc. (BBIO). The filing indicates a proposed sale of 2808 shares of common stock with an aggregate market value of $190,944.00, acquired through a stock option exercise on June 22, 2026. The sale is being handled by Morgan Stanley Smith Barney LLC and is intended for trading on NASDAQ.
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
BridgeBio Pharma, Inc. announced that additional positive data from its Phase 3 PROPEL 3 pivotal study of oral infigratinib for children with achondroplasia will be shared at the International Congress of Children’s Bone Health (ICCBH) 2026. The company will deliver a late-breaking oral presentation on the randomized controlled trial results, along with other oral presentations and posters detailing quality of life studies, early intervention research, observational findings, and educational resources for achondroplasia and related skeletal dysplasias patients. BridgeBio will also present findings from its CLARIFY disease monitoring study for autosomal dominant hypocalcemia type 1 and 2.
